Meet Some of AIChE’s Recently Elected Fellows
Candidates for AIChE Fellow are nominated by their peers, and must have significant chemical engineering experience (generally 25 years), have demonstrated significant service to the profession, and have been a member of AIChE for at least 10 years. Here are some of the recently elected Fellows. More Fellows will be introduced in future issues of CEP.
Christopher Burcham is an Executive Director in the Synthetic Molecule Design and Development Dept. at Eli Lilly, where he leads the Solid Dispersion Engineering Group and is responsible for the technical oversite and advancement of spray drying and other absorption-enabling platforms. Prior to this role, he was the Scientific Team Leader for Reyvow (lasmiditan), a new selective serotonin 5-HT1F agonist for treatment of acute migraines in adults. He was also responsible for overseeing all aspects of drug substance and drug product development, including process and product development, regulatory registration, and technology transfer into Lilly’s manufacturing operations.
Mark K. Cox is a veteran Fortune 500 executive. He was Chief Manufacturing, Supply Chain and Engineering Officer for Eastman, from which he retired following a 36-year career. His global business leadership background includes innovation and operations experience, and he holds U.S. and international patents associated with process technologies developed by Eastman. He is also a board member of numerous organizations. A longtime AIChE member, he has served in roles ranging from participation on the Program Committee to presenting keynote talks at the Global Congress on Process Safety. He has also championed Eastman’s efforts as a Founders Circle company in the AIChE Foundation’s Doing a World of Good campaign.
Timothy Dodge is Chief Engineer and Technical Fellow at International Flavors and Fragrances (IFF). He has been with the organization for nearly 40 years — as the company evolved from Eastman Kodak, to Genencor International, to Danisco, to DuPont, before becoming IFF. Dodge was involved in the early years of industrial metabolic engineering (synthetic biology), with most of his career spent producing industrial enzymes — resulting in hundreds of products with total annual sales of more than $300 million. He also lectures on industrial biotechnology at Stanford Univ., UC Berkeley, UCLA, and his alma maters, the Univ. of Michigan and the Univ. of Minnesota.
Paul Mensah is the Senior Vice President and Head of Biotherapeutics Pharmaceutical Sciences at Pfizer Inc. His organization is responsible for the development of Pfizer’s expansive and diverse biotherapeutic, gene therapy, and vaccine portfolio, including the manufacture of early...
Would you like to access the complete CEP Article?
No problem. You just have to complete the following steps.
You have completed 0 of 2 steps.
-
Log in
You must be logged in to view this content. Log in now.
-
AIChE Membership
You must be an AIChE member to view this article. Join now.
Copyright Permissions
Would you like to reuse content from CEP Magazine? It’s easy to request permission to reuse content. Simply click here to connect instantly to licensing services, where you can choose from a list of options regarding how you would like to reuse the desired content and complete the transaction.